Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Markets are closed but DD never stops.
Wow great points. No argument here. I will save this post to remind me why I sold earlier. I hope things work out but I am very skeptical. Thank you for the detailed response.
Explosive sales won't guarantee dilution will stop. I don't trust this CEO. Would consider getting back in if:
Dilution stops
Q's are audited
51% becomes 100%
GLTA
Wording matters. I think Tomas learned a lesson. No one is perfect.
RMAT was a means to end (still could be). But now it has shifted to the clinics and Texa$.
I feel pretty good.
"what did Kristin say about when to collect adult stem cells"
Get then while they're hot? lol
No. Get them early.
Young company.
Young industry.
Hope you're right my ole friend.
Doesn't make sense. But GLTY.
Very true indeed.
USRM$
Good article. Mentioning the clinics is nice (to include Dallas). But they could have talked about the Patient-Centered Stem Cell Therapy Bill Passed by Texas Legislature and how this can have a significant positive impact on USRM going forward.
Holding for 6 months now. My arms are getting tired..lol Need a pop soon:)
Why is the stock above .05? Were is the tangible book value to back up this share price? Any justification for this run other than phase II? Is this just another P&D? .05 to .30 then crash?
Yes. Bright bold colors too. HD = High Definition..lol
Stem cell tech is the future.
USRM$
Undervalued is key. This stock was way oversold. It's time to move back up.
It's moving. They have announced plans. Guidance has been set. Patience.
RMAT is still in play. Draft guidance matters. Should USRM continue to burn cash every time the FDA stalls for more info as Q2 approaches? Last time I checked, the FDA director position was vacant. There are other options for commercialization. In the meantime, once guidance is determined USRM will have more clarity on how to present data. I think the FDA will come around eventually because -- Trump, Gottlieb, public demand, and global competition will create positive change.
Things are looking up.
Ah-ha. Well the cream rises.
Yeah
Disagree
This wants to run.
This is my specialty. 30 years in orthopaedics. Those results are encouraging. Thanks for the link.
Makes sense there is more to the story. Maybe that had some influence on the wording used in his blog to postpone RMAT?
Focusing on patient care is the key to USRM's success more than RMAT at this particular juncture imo.
There is plenty of time to make up ground. Although I hope you are right, daily predictions can lead to disappointment. When there is value patience is key.
Yes lol. Great movie. Bruce Willis and the kid might have been dead, but this stock isn't.
Wasn't it? I think many people got schooled today. The stock market prays on emotion. Just ask Hornet and Snug.
It's just getting started.
Wouldn't surprise me.
lol
USRM$
Thank you HH.
It is a lot of money to throw away emit which is what USRM was doing dealing with RMAT. Tomas has a responsivity to turn a profit. The Texas law was a convenient circumstance to drop RMAT for now.
Did you see the cost for sending in more documentation? What a rip off. This is a way to keep the smaller businesses from competing with big pharma. FDA is corrupt. Hopefully Gottlieb can make a difference.
Your opinion is spot on. Nice post.
Up listing would be nice.. Patience, profit and positive customer feedback will drive it there.
Yep.
My hangover is gone. F..k the FDA. I have moved on from RMAT.
USRM$ long play.
Fees:
New Drug Application (With Clinical Data) $2,038,100 FY 2017
New Drug Application Supplement With Clinical Data $1,019,050
http://www.raps.org/Regulatory-Focus/News/2016/08/01/25478/FDA-Unveils-User-Fee-Rates-for-FY-2017/
Not cheap. I think Tomas did the right thing. Make money now. Pursue RMAT (if needed) later. Texas provides a huge opportunity for income and advertisement. Other states will want a piece of the pie. I like the future here.
Very reasonable. I am holding long too. Next week will be interesting.
You are one of the few that has been consistently focusing on the business of USRM - things they can control. You are a wise one indeed. Props to you my friend.
I agree with much of what you have said. I'm going to ride it out. If RMAT was that significant of a factor to valuation the s/p would be much higher than it is now. Tomas provided clarity which is significant for an investor like myself.
Oh soo good. Nice post bro.